3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase EARLY_PHASE1
1
Status
Completed
52
Terminated
11
Unknown
3
Active not recruiting
3
Withdrawn
2
Recruiting
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Neoplasms
1
Interventions
pembrolizumab
223
Carboplatin
222
Specimen Handling
194
Cisplatin
192
Magnetic Resonance Spectroscopy
165
Radiotherapy
153
Bevacizumab
143
Gemcitabine
136
Cyclophosphamide
135
Drug Therapy
119
Capecitabine
118
Paclitaxel
116
Oxaliplatin
111
Nivolumab
105
Biopsy
104
venetoclax
103
tislelizumab
83
Rituximab
83
durvalumab
82
toripalimab
78
Fluorouracil
73
Etoposide
72
Docetaxel
69
Dexamethasone
69
sintilimab
67
Pemetrexed
67
atezolizumab
65
Radiosurgery
65
Azacitidine
63
130-nm albumin-bound paclitaxel
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
temsirolimus
×
Clear all
NCT02693535
2026-05-15
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled